Identification of the transforming STRN-ALK fusion asa potential therapeutic target in the aggressive forms of thyroid cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 11, 2014, Pages 4233-4238

  Kelly, Lindsey M ^a   Barila, Guillermo ^a   Liu, Pengyuan ^b   Evdokimova, Viktoria N ^a   Trivedi, Sumita ^a   Panebianco, Federica ^a   Gandhi, Manoj ^a   Carty, Sally E ^a   Hodak, Steven P ^c   Luo, Jianhua ^a   Dacic, Sanja ^a   Yu, Yan P ^a   Nikiforova, Marina N ^a   Ferris, Robert L ^a   Altschuler, Daniel L ^a   Nikiforov, Yuri E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; HYBRID PROTEIN; PROTEIN KINASE; STRIATIN PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL GROWTH; DIMERIZATION; ENZYME INHIBITION; EXPRESSION VECTOR; FUSION GENE; GENE EXPRESSION; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN TARGETING; RNA SEQUENCE; THYROID CANCER;

BASE SEQUENCE; BLOTTING, WESTERN; CALMODULIN-BINDING PROTEINS; GENE FUSION; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PYRAZOLES; PYRIDINES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, RNA; THYROID NEOPLASMS; TRANSCRIPTOME;

EID: 84896531092     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1321937111     Document Type: Article

References (33)

1. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103(7):1330-1335.
2. Smallridge RC, Copland JA (2010) Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 22(6):486-497.
3. Volante M, et al. (2009) RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab 94(12):4735-4741.
4. Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13(3):184-199.
5. Nikiforov YE, Nikiforova MN (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7(10):569-580.
6. Vogelstein B, et al. (2013) Cancer genome landscapes. Science 339(6127):1546-1558.
7. Soda M, et al. (2007) Identification of the transforming EML4-ALK fusion gene in nonsmall- cell lung cancer. Nature 448(7153):561-566. (Pubitemid 47206930)
8. Stephens PJ, et al. (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144(1):27-40.
9. Castets F, et al. (1996) A novel calmodulin-binding protein, belonging to the WDrepeat family, is localized in dendrites of a subset of CNS neurons. J Cell Biol 134(4): 1051-1062. (Pubitemid 26278227)
10. Moqrich A, et al. (1998) Cloning of human striatin cDNA (STRN), gene mapping to 2p22-p21, and preferential expression in brain. Genomics 51(1):136-139. (Pubitemid 28373383)
11. Lee CC, et al. (2010) Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 430(3):425-437.
12. Donella-Deana A, et al. (2005) Unique substrate specificity of anaplastic lymphoma kinase (ALK): Development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry 44(23):8533-8542. (Pubitemid 40799935)
13. Chen Y, et al. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455(7215):971-974.
14. Kwak EL, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693-1703.
15. Heuckmann JM, et al. (2011) ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 17(23):7394-7401.
16. Mitelman F (2000) Recurrent chromosome aberrations in cancer. Mutat Res 462(2-3): 247-253. (Pubitemid 30190232)
17. Rabbitts TH (1994) Chromosomal translocations in human cancer. Nature 372(6502): 143-149. (Pubitemid 24347832)
18. Grieco M, et al. (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60(4): 557-563.
19. Santoro M, et al. (1994) Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 9(2):509-516. (Pubitemid 24041530)
20. Nikiforov YE (2002) RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13(1): 3-16. (Pubitemid 34665111)
21. Chinnaiyan AM, Palanisamy N (2010) Chromosomal aberrations in solid tumors. Prog Mol Biol Transl Sci 95:55-94.
22. Levin JZ, et al. (2009) Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biol 10(10):R115.
23. Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7):2640-2653. (Pubitemid 40446252)
24. Morris SW, et al. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263(5151):1281-1284. (Pubitemid 24107549)
25. Murugan AK, Xing M (2011) Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 71(13):4403-4411.
26. Leeman-Neill RJ, et al. (2013) RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer 119(10):1792-1799.
27. Christensen JG, et al. (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6(12 Pt 1):3314-3322.
28. Cui JJ, et al. (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54(18):6342-6363.
29. Sakamoto H, et al. (2011) CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19(5):679-690.
30. Katayama R, et al. (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 108(18):7535-7540.
31. Armstrong F, et al. (2004) Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 23(36): 6071-6082. (Pubitemid 39178860)
32. Heuckmann JM, et al. (2012) Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 18(17):4682-4690.
33. Lovly CM, et al. (2011) Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 71(14):4920-4931.